Glaucoma: Diagnosis and Management

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Clinical Diagnosis and Prognosis".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 1015

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Surgical, Medical, Molecular Pathology and Critical Care Medicine, University of Pisa, 56126 Pisa, Italy
2. Ophthalmology, Department of Medical and Surgical Specialties, Azienda Ospedaliero Universitaria Pisana, 56124 Pisa, Italy
Interests: glaucoma; cataract; uveitis

Special Issue Information

Dear Colleagues,

Glaucoma, a progressive eye disease affecting the optic nerve, is a leading cause of irreversible blindness worldwide. It often develops slowly and without noticeable symptoms until significant vision loss occurs. Diagnosis typically involves measuring intraocular pressure, assessing optic nerve head morphology, and visual field testing.

The management of glaucoma aims to reduce intraocular pressure to prevent further damage to the optic nerve and preserve vision. Treatment options include prescription eye drops, laser therapy such as selective laser trabeculoplasty (SLT), and surgical procedures like microinvasive glaucoma surgery (MIGS), minimally invasive bleb surgery (MIBS), trabeculectomy, or drainage implants.

Regular monitoring and adherence to treatment plans are essential for managing glaucoma effectively. Early detection through routine eye exams is key in initiating timely intervention to slow disease progression and maintain visual function. By raising awareness about the importance of regular eye screenings and adhering to treatment regimens, individuals can take proactive steps to preserve their vision and quality of life.

In this Special Issue, we invite contributions that discuss new technologies, emerging service models, and insights into current and future surgical procedures. Original articles, reviews, and reports are welcome to contribute to this discussion.

Dr. Chiara Posarelli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glaucoma
  • adherence
  • MIBS (minimally invasive bleb surgery)
  • MIGS (microinvasive glaucoma surgery)
  • artificial intelligence

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 1629 KiB  
Article
Comparison of the Intraocular Pressure-Lowering Effect of Minimally Invasive Glaucoma Surgery (MIGS) iStent Inject W and Hydrus—The 12-Month Real-Life Data
by Cedric Weich, Julian Alexander Zimmermann, Jens Julian Storp, Ralph-Laurent Merté, Nicole Eter and Viktoria Constanze Brücher
Diagnostics 2025, 15(4), 493; https://doi.org/10.3390/diagnostics15040493 - 18 Feb 2025
Viewed by 677
Abstract
Background/Objectives: To compare the efficacy and safety of Hydrus® Microstent and iStent inject® W implants, in combination with phacoemulsification, for lowering intraocular pressure (IOP) in patients with glaucoma in a real-world clinical setting. Methods: This retrospective, single-center study analyzed medical records [...] Read more.
Background/Objectives: To compare the efficacy and safety of Hydrus® Microstent and iStent inject® W implants, in combination with phacoemulsification, for lowering intraocular pressure (IOP) in patients with glaucoma in a real-world clinical setting. Methods: This retrospective, single-center study analyzed medical records of glaucoma patients who underwent either Hydrus® Microstent or iStent inject® W implantation combined with cataract surgery at the University Hospital Muenster, Germany. Key outcome measures included absolute and relative IOP reduction, reduction in topical antiglaucoma medication use, overall success rate, and complications. A total of 32 eyes were analyzed, 16 in each treatment group, with a 12-month follow-up. Results: Both groups demonstrated significant postoperative IOP reduction (Hydrus: p < 0.001; iStent inject® W: p = 0.032). The Hydrus group achieved significantly greater relative IOP reduction compared to the iStent inject® W group (p = 0.043). The Hydrus group also showed a significant reduction in daily antiglaucoma medication use (p = 0.002), whereas the iStent inject® W group did not achieve statistical significance in this regard (p = 0.054). The overall success rate was higher in the Hydrus group (38%) than in the iStent inject® W group (13%), though the difference was not statistically significant (p = 0.102). No device-related complications were observed in either group. Conclusions: The Hydrus® Microstent demonstrated superior IOP reduction and a more significant reduction in the need for antiglaucoma medications compared to the iStent inject® W in a real-world setting. These findings support the use of the Hydrus implant as an effective and safe micro-invasive glaucoma surgery (MIGS) option for patients with mild to moderate POAG. Further studies with larger patient populations and long-term follow-up are warranted to confirm the efficacy in patients with PEX and advanced glaucoma. Full article
(This article belongs to the Special Issue Glaucoma: Diagnosis and Management)
Show Figures

Figure 1

Back to TopTop